Abstract:Carboxylesterases (CESs, E.C.3.1.1.1) constitute a large class of enzymes that determine the therapeutic efficacy and toxicity of ester/amide drugs. Without exceptions, all mammalian species studied express multiple forms of carboxylesterases. Two human carboxylesterases, CES1 and CES2, are major contributors to hydrolytic biotransformation. Recent studies have identified therapeutic agents that potently inhibit carboxylesterases-based catalysis. Some of them are reversible whereas others irreversible. The adrenergic antagonist carvedilol, for example, reversibly inhibits CES2 but this carboxylesterase is irreversibly inhibited by orlistat, a popular anti-obesity medicine. Kinetically, the inhibition occurs competitively, non-competitively or in combination, depending on a carboxylesterase. For example, the calcium channel blocker diltiazem competitively inhibits CES1 but non-competitively inhibits CES2. In addition to inhibited catalysis, several therapeutic agents or disease mediators have been shown to regulate the expression of carboxylesterases. For example, the antiepileptic drug phenobarbital induces both human and rodent carboxylesterases, whereas the antibiotic rifampicin induces human carboxylesterases only. Conversely, the proinflammatory cytokine interleukin-6 (IL-6) suppresses the expression of carboxylesterases across species, but depending on the concentrations of glucose in the culture medium. Transactivation, transrepression and altered mRNA stability contribute to the regulated expression. Several nuclear receptors are established to support the regulation including constitutive androstane receptor, glucocorticoid receptor and pregnane X receptor. In addition, non-ligand transcription factors are also involved in the regulation and exemplified by differentiated embryo chondrocyte-1, nuclear factor (erythroid-derived 2)-like 2 and tumor protein p53. These transcription factors coordinate the regulated expression of carboxylesterases, constituting a regulatory network for the hydrolytic biotransformation.

Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and other Transcription Factors

Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism

Transcription Factor-Mediated Regulation Of Carboxylesterase Enzymes In Livers Of Mice

Insulin Transcriptionally Down-Regulates Carboxylesterases Through Pregnane X Receptor in an Akt-dependent Manner.

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators

Carboxylesterase-2 is a Highly Sensitive Target of the Antiobesity Agent Orlistat with Profound Implications in the Activation of Anticancer Prodrugs.

Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity

17Β-Estradiol Suppresses Carboxylesterases by Activating C-Jun/ap-1 Pathway in Primary Human and Mouse Hepatocytes.

Recent Progress in the Discovery of Natural Inhibitors Against Human Carboxylesterases

Synthesis and Structure‐Activity Relationships of 3‐Arylisoquinolone Analogues as Highly Specific hCES2A Inhibitors

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism

Dexamethasone Suppresses the Expression of Multiple Rat Carboxylesterases Through Transcriptional Repression: Evidence for an Involvement of the Glucocorticoid Receptor

Investigation of the inhibitory effect of protostanes on human carboxylesterase 2 and their interaction: Inhibition kinetics and molecular stimulations

In Vitro Drug Metabolism by Human Carboxylesterase 1: Focus on Angiotensin-Converting Enzyme Inhibitors

Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology

Characterization of Recombinant Human Carboxylesterases: Fluorescein Diacetate as a Probe Substrate for Human Carboxylesterase 2

Discovery of pyrazolones as novel carboxylesterase 2 inhibitors that potently inhibit the adipogenesis in cells

Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor

Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2